Antiretroviral therapy in the treatment-experienced patient
- PMID: 12737118
Antiretroviral therapy in the treatment-experienced patient
Abstract
Despite the growing number of new antiretroviral agents, planning therapy for treatment-experienced patients remains extremely challenging. Cross-resistance within the three currently available classes of drugs limits the number of sequential drug regimens that can be expected to suppress viral replication effectively. An understanding of resistance and cross-resistance, together with judicious use of resistance testing, can help clinicians design better treatment regimens for patients experiencing virologic failure while taking antiretroviral therapy.
Similar articles
-
Assessing resistance costs of antiretroviral therapies via measures of future drug options.J Infect Dis. 2003 Oct 1;188(7):1001-8. doi: 10.1086/378355. Epub 2003 Sep 23. J Infect Dis. 2003. PMID: 14513420
-
Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?AIDS Rev. 2008 Oct-Dec;10(4):205-11. AIDS Rev. 2008. PMID: 19092976 Review.
-
Bridging the gap. Bringing new antiretroviral medications into the clinic.Adv Nurse Pract. 1999 Jan;7(1):24-30; quiz 31-2. Adv Nurse Pract. 1999. PMID: 10030167 Review.
-
Initiation of antiretroviral therapy: implications of recent findings.Top HIV Med. 2004 Jul-Aug;12(3):83-8. Top HIV Med. 2004. PMID: 15310939 Review.
-
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.J Infect Dis. 2004 Jul 15;190(2):285-92. doi: 10.1086/422007. Epub 2004 Jun 11. J Infect Dis. 2004. PMID: 15216463
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical